Results 151 to 160 of about 37,428 (161)

Clinical features of dominant and recessive interferon γ receptor 1 deficiencies

Lancet, The, 2004
Capucine Picard, Sergio D Rosenzweig, Melanie J Newport   +2 more
exaly  

Interferon

Ca-A Cancer Journal for Clinicians, 1972
exaly  

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

Lancet, The, 2001
Giancarlo Comi, Massimo Filippi, Frederik Barkhof   +2 more
exaly  

Interferon and Cancer Treatment

Ca-A Cancer Journal for Clinicians, 1978
exaly  

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Lancet, The, 2007
Alain Ravaud, Sergio Bracarda, C?zary A Szczylik   +2 more
exaly  

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Lancet, The, 2005
Harry La Janssen, Yilmaz Cakaloglu, Guido Gerken   +2 more
exaly  

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

Lancet, The, 2001
exaly  

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Lancet, The, 2008
Mario Santinami, Alessandro A E Testori, Reinhard Dummer   +2 more
exaly  

Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

Lancet, The, 1998
exaly  

Interferon-stimulated neutrophils as a predictor of immunotherapy response

Cancer Cell
Yuval Shaked
exaly